Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jacobio Pharmaceuticals Co., Ltd.
With
AbbVie
To assess the safety and tolerability and determine the recommended phase 2 dose (RP2D) of JAB-3068 in combination with PD1 inhibitor in patients with advanced solid tumors.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses.
Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF).
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
You may not be if
History (≤3 years) of cancer that is histologically distinct from the cancers under study, except for cervical carcinoma in situ, superficial non-invasive bladder tumors, or curatively treated Stage I non-melanoma skin cancer
Known serious allergy to experimental drugs
Brain or spinal metastases, except if treated by surgery, surgery plus radiotherapy or radiotherapy alone, with no evidence of progression or hemorrhage for ≤21 days before the start of treatment with the study drugs, and has not received any systemic corticosteroids for ≥21 days before the start of treatment with the study drugs
Clareo Health | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
